%0 Journal Article
%T IL-36受体拮抗剂治疗泛发性脓疱型银屑病的机制及研究进展<br>Mechanism and Progress of Interleukin-36 Receptor Antagonistin the Treatment of Generalized Pustular Psoriasis
%A 杨晶
%A 肖异珠
%J Advances in Clinical Medicine
%P 4559-4564
%@ 2161-8720
%D 2022
%I Hans Publishing
%R 10.12677/ACM.2022.125658
%X 泛发性脓疱型银屑病(Generalized Pustular Psoriasis, GPP)是一种感染、遗传及免疫等多因素介导的慢性炎症性皮肤病，其治疗困难，病情可迁延不愈，并合并多器官功能损害，对患者生理健康造成重大影响。近年来国内外发现IL36RN突变是GPP的主要致病基因，IL-36信号通路成为了其发病机制重要的一环，在此基础上提出并研究了IL-36受体拮抗剂对GPP的靶向药物治疗并取得了突破性进展Spesolimab (司柏索利)的产生。作为一种新的IL-36R单克隆抗体，通过阻断IL-36R信号通路达到治疗GPP的作用，进一步了解IL-36受体拮抗剂治疗机制及目前研究进展，对中国泛发性脓疱型银屑病患者有着重要临床意义。<br />
Generalized Pustular Psoriasis is a chronic inflammatory skin disease, mediated by many factors such as infection, heredity and immunity. It is difficult to be treated, has a significant impact on the patient’s physical health. In recent years, the mutation of IL36RN has been found to be the major pathogenic gene of GPP, and the IL-36 signal pathway has become an important link in the patho-genesis of GPP. On this basis, we proposed and studied the target drug therapy for GPP by IL-36 re-ceptor antagonist and made a breakthrough progress, Spesolimab. As a new biologics of IL-36R, it can interdict the signal pathway of IL-36R to treat GPP, as to further understand the mechanism of IL-36R antagonist therapy and the current research progress, has important clinical significance for Chinese patients with generalized pustular psoriasis.
%K 泛发性脓疱型银屑病，IL-36受体拮抗剂，Spesolimab，生物制剂<br>Generalized Pustular Psoriasis
%K Interleukin-36 Receptor Antagonist
%K Spesolimab
%K Biologics
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=51760